Should I Buy TPST? TPST 2026 Analysis

Should You Buy Tempest Therapeutics Inc (TPST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.810

1 Day change

0.72%

52 Week Range

12.610

Analysis Updated At

2026/01/26

Tempest Therapeutics Inc (TPST) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear bullish signals from technical analysis, options data, and proprietary trading signals. Additionally, the company's financial performance is weak, and while there are some positive catalysts, they are not sufficient to justify a buy recommendation at this time.

Technical Analysis

The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral at 62.171, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 3.058 and 3.235, while support levels are at 2.485 and 2.308. Overall, the technical indicators do not strongly support a buy decision.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analyst upgrade by H.C. Wainwright with a price target of $11, citing a strategic pivot and acquisition of CAR-T programs.
Announcement of warrants distribution, which could potentially increase shareholder value if Proposal 5 is approved.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025, with a significant drop in net income (-66.74% YoY) and EPS (-85.15% YoY).
Lack of significant insider or hedge fund trading activity, indicating neutral sentiment.
No recent congress trading data or influential figure involvement.

Financial Performance

In Q3 2025, revenue remained at $0, showing no growth. Net income dropped significantly to -$3.51M (-66.74% YoY), and EPS fell to -0.79 (-85.15% YoY). Gross margin remained at 0%. Overall, the financial performance is weak and does not support a buy recommendation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright upgraded the stock to Buy with an $11 price target, citing the acquisition of CAR-T programs and a strategic pivot as positive moves. However, the company's financial struggles and lack of immediate growth potential limit the impact of this upgrade.

Analyst Rating

Wall Street analysts forecast TPST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TPST is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 2.790

Low

Averages

High

Current: 2.790

Low

Averages

High

H.C. Wainwright

Joseph Pantginis

Neutral -> Buy

upgrade

$11

AI Analysis

2026-01-22

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$11

AI Analysis

2026-01-22

upgrade

Neutral -> Buy

Reason

H.C. Wainwright analyst Joseph Pantginis upgraded Tempest Therapeutics to Buy from Neutral with an $11 price target. The company's acquisition of Factor Bioscience's CAR-T programs is a "shrewd and necessary move" to extend its "critically short cash runway into 2027," the analyst tells investors in a research note. The firm Tempest's strategic pivot also expands the company's pipeline with a "clinically de-risked" cell therapy asset TPST-2003. It cites Tempest's renewed strategic focus and market opportunity for the upgrade.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Hold

Downgrades

$16

2025-04-10

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-04-10

Downgrades

Strong Buy

Hold

Reason

Tempest Therapeutics announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage programs. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisition, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company has retained MTS Health Partners, a financial advisor with experience in the biotechnology industry, to support it with the strategic evaluation process. "Notwithstanding the positive randomized data set from the amezalpat Phase 2 and its blockbuster potential in first-line HCC, as well as the potential of TPST-1495 as it moves towards a Phase 2 in FAP, the capital markets have been unavailable to support the next stage of advancement," said Stephen Brady, president and chief executive officer of Tempest. "We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include finding a strategic partner with the resources to develop what we believe are potentially life-saving therapies for patients in need. Given the positive data and commercial potential with this pipeline, as well as the clearance from FDA on the lead program's pivotal study, we believe this is a rare opportunity for a partner."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TPST

Unlock Now

TPST Should I Buy

TPST Should I Buy

Should You Buy Tempest Therapeutics Inc (TPST) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch